Economic burden of brain metastases in patients with non-small cell lung cancer: costs and implications

Brain metastases are prevalent in patients with lung cancer. Up to 30% of the lung cancer patients will develop brain metastases during the course of their disease (1). Additional supportive treatments with or without brain-directed therapies are anticipated and the economic burden is undeniably substantial after the diagnosis (2).